Nuvectis Pharma (NVCT) Treasury Shares (2021 - 2026)
Nuvectis Pharma (NVCT) posted Treasury Shares of $2.9 million for Q1 2026, up 29.54% sequentially from $2.2 million in Q4 2025, and up 36.55% YoY from $2.1 million in Q1 2025.
Nuvectis Pharma (NVCT) Treasury Shares (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Treasury Shares for 5 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Treasury Shares rose 36.55% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 36.55% YoY) and the FY2025 annual result came in at $2.2 million, up 63.03% from the prior year.
- Treasury Shares climbed to $2.9 million in Q1 2026 per NVCT's latest filing, from $2.2 million in the prior quarter.
- Over five years, Treasury Shares peaked at $2.9 million in Q1 2026 and troughed at $941496.0 in Q4 2023.
- A 4-year average of $1.9 million and a median of $2.1 million in 2025 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2025 and 2026: Treasury Shares jumped 63.03% in 2025, then soared 36.55% in 2026.
- Over 4 years, Treasury Shares stood at $941496.0 in 2023, then surged by 45.06% to $1.4 million in 2024, then surged by 63.03% to $2.2 million in 2025, then grew by 29.54% to $2.9 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $2.9 million, $2.2 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Mn |
| Jun 30, 2026 | 2.88 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Dec 31, 2023 | 941,496.00 |
| Dec 31, 2023 | 941,496.00 |